Microbial pathogenesis · 2025
Biosynthesized gold nanoparticles from Proteus mirabilis: A synergistic strategy against multidrug-resistant Gram-negative bacteria.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ibrahem Kawther Hkeem, Abdulaziz Sazan Moffaq, Haji Sayran Hamad, Ganjo Aryan R, Bhardwaj Nidhi, Bhardwaj Indu, Ghosh Soumya
Аннотация
Gold nanoparticles (AuNPs) are increasingly explored as antimicrobial agents for the detection and treatment of multidrug-resistant (MDR) bacterial infections. This research tries to establish an eco-friendly, biological process for synthesizing AuNPs using Proteus mirabilis and studies their antibacterial efficacy against MDR Gram-negative pathogens and their potential to enhance standard antibiotic efficacy. Using the Vitek-2 system, 51 P.mirabilis isolates were analyzed, of which 74.5 % were MDR. Netilmicin was effective against 75 % of these isolates. P.mirabilis extracellularly biosynthesized AuNPs, which were then characterized by XRD, FTIR, TEM, and FE-SEM. Characterization showed AuNPs measuring ∼6-12 nm in size; the presence of amino and amide groups from FTIR spectra; and predominantly spherical or ellipsoidal morphology. Antibacterial activity, through broth microdilution, revealed that biosynthesized AuNPs inhibited Gram-negative bacilli at MICs of 156-1250 μg/mL. Moreover, biosynthesized AuNPs enhanced the effectiveness of antibiotics at low concentrations. Notably, when biosynthesized AuNPs were combined with ceftriaxone (commercial antibiotic), a marked synergistic effect was observed (P < 0.0001), with significantly enhanced prevention of pathogens compared to ceftriaxone used alone. These findings marched the function of biosynthesized AuNPs as adjuvants in drug development against MDR infections.